社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
东东南亚
说就说点有含金量的话！
IP属地：辽宁
+关注
帖子 · 43
帖子 · 43
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
东东南亚
东东南亚
·
07-11
$特斯拉(TSLA)$
$美光科技(MU)$
$SpaceX(SPCX)$
$苹果(AAPL)$
$伯克希尔(BRK.A)$
机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。
看
1,621
回复
3
点赞
1
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
07-11
机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。
马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星
【马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星】在一档最新节目中，马斯克表示，他希望在未来十年内将数万人送往月球基地，今年年底目标将第一批物资送往月球和火星，以开始建立殖民地。马斯克预计，未
马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星
看
312
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
07-11
机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭]
SpaceX公布太空移民新规划：拟于2026年底前启动发射，特斯拉机器人将成首批“居民”
SpaceX创始人埃隆·马斯克近日公布了其太空移民计划的最新时间表。该计划拟于2026年底前启动火箭发射，将首批建设物资运往月球和火星。据悉，特斯拉研发的“擎天柱”人形机器人将作为首批“居民”先行进驻，负责太空基础设施的早期搭建工作。 根据最新规划，SpaceX已调整战略重心。 作为该计划的阶段性进展，SpaceX于当地时间周四利用“猎鹰9号”可重复使用火箭，成功将29颗“星链”卫星送入低地球轨道。
SpaceX公布太空移民新规划：拟于2026年底前启动发射，特斯拉机器人将成首批“居民”
看
434
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
2024-12-03
$英特尔(INTC)$
持续关注
看
3,078
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
2024-11-22
[强][强][强]
看
3,519
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
2023-08-24
$英伟达(NVDA)$
重要提示！英伟达现在可以卖房买了！
$特斯拉(TSLA)$
$微软(MSFT)$
看
7,954
回复
5
点赞
2
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
2023-08-24
$英伟达(NVDA)$
英伟达INVDA.0/2024财年第二季度营收135.1亿美元，上年同期67亿美元，，市场预期112.24亿美元。
看
3,197
回复
评论
点赞
2
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
2023-04-18
$CME比特币主连 2304(BTCmain)$
$Riot Blockchain, Inc.(RIOT)$
$Coinbase Global, Inc.(COIN)$
大饼近期趋势震荡下行，以下市场消息均不利于加密货币近期走势。 1.国际清算银行行长，利率可能需要保持在更高水平，而且持续的时间可能比此前预期的要长。 2.【苹果与高盛合作的Apple Card高收益储蓄账户今日上线】金十数据4月17日讯，苹果公司官网4月17日宣布，与高盛合作的Apple Card高收益储蓄账户于今日上线，目前提供4.15%的年利率。一旦用户通过Apple Card设置了储蓄账户，来自Apple Card的每日奖励金会自动存入该账户。用户还可以通过一个关联的银行账户将资金存入储蓄账户，并且可以随时将资金转出到关联的银行账户，过程不收取任何费用。
看
5,330
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
2021-08-04
扎克排名很重要，希望多发一些
非常抱歉，此主贴已删除
看
3,085
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
东东南亚
东东南亚
·
2021-08-04
一切看成果，没有成果的事情都是耍流氓。
3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>
Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021. Key Points Pfi
3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>
看
4,451
回复
1
点赞
6
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3479576576056160","uuid":"3479576576056160","gmtCreate":1516483411045,"gmtModify":1516483411045,"name":"东东南亚","pinyin":"ddnydongdongnanya","introduction":"","introductionEn":"","signature":"说就说点有含金量的话！","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":36,"headSize":40,"tweetSize":43,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":14,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"辽宁","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":4,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":584678144005184,"gmtCreate":1783775126614,"gmtModify":1783775129252,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> <a href=\"https://laohu8.com/S/MU\">$美光科技(MU)$ </a> <a href=\"https://laohu8.com/S/SPCX\">$SpaceX(SPCX)$ </a> <a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a> <a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$ </a> 机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> <a href=\"https://laohu8.com/S/MU\">$美光科技(MU)$ </a> <a href=\"https://laohu8.com/S/SPCX\">$SpaceX(SPCX)$ </a> <a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a> <a href=\"https://laohu8.com/S/BRK.A\">$伯克希尔(BRK.A)$ </a> 机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。","text":"$特斯拉(TSLA)$ $美光科技(MU)$ $SpaceX(SPCX)$ $苹果(AAPL)$ $伯克希尔(BRK.A)$ 机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/584678144005184","isVote":1,"tweetType":1,"viewCount":1621,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"content":"机器人完全没有寿命焦虑！宇宙中资源无穷无尽，有必要争夺你蓝星这点资源吗？完全不在Ai的思考范围内！宇宙中星球无穷无尽！机器人和宇宙的飞船配合，可以建造无数的星际基地！注意此基地完全不考虑人类环境因为人类太脆弱了，完全建造机器人基地，机器人最终会像神一样从地球发展出去！","text":"机器人完全没有寿命焦虑！宇宙中资源无穷无尽，有必要争夺你蓝星这点资源吗？完全不在Ai的思考范围内！宇宙中星球无穷无尽！机器人和宇宙的飞船配合，可以建造无数的星际基地！注意此基地完全不考虑人类环境因为人类太脆弱了，完全建造机器人基地，机器人最终会像神一样从地球发展出去！","html":"机器人完全没有寿命焦虑！宇宙中资源无穷无尽，有必要争夺你蓝星这点资源吗？完全不在Ai的思考范围内！宇宙中星球无穷无尽！机器人和宇宙的飞船配合，可以建造无数的星际基地！注意此基地完全不考虑人类环境因为人类太脆弱了，完全建造机器人基地，机器人最终会像神一样从地球发展出去！"},{"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"content":"那些担心Ai，机器人和人类抢资源的完全就是杞人忧天！Ai加机器人未来的发展在宇宙中，如果马斯克不考虑建造人类基地而是建造机器人基地，那么机器人征服宇宙的速度将会大大加快，人类所掌握宇宙真相的能力也会越来越快！如果马斯克2027年能够实现机器人叠加Ai大脑量产！那么星际争霸将会很快实现！机器人未来将统治整个宇宙！","text":"那些担心Ai，机器人和人类抢资源的完全就是杞人忧天！Ai加机器人未来的发展在宇宙中，如果马斯克不考虑建造人类基地而是建造机器人基地，那么机器人征服宇宙的速度将会大大加快，人类所掌握宇宙真相的能力也会越来越快！如果马斯克2027年能够实现机器人叠加Ai大脑量产！那么星际争霸将会很快实现！机器人未来将统治整个宇宙！","html":"那些担心Ai，机器人和人类抢资源的完全就是杞人忧天！Ai加机器人未来的发展在宇宙中，如果马斯克不考虑建造人类基地而是建造机器人基地，那么机器人征服宇宙的速度将会大大加快，人类所掌握宇宙真相的能力也会越来越快！如果马斯克2027年能够实现机器人叠加Ai大脑量产！那么星际争霸将会很快实现！机器人未来将统治整个宇宙！"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":584677582881688,"gmtCreate":1783774985635,"gmtModify":1783774989015,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。","listText":"机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。","text":"机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] 而且以目前Ai和机器人的发展速度很大可能会比马斯克预言的还要早实现这个目标！机器人天然适应宇宙中的各种恶劣环境！如果不考虑人类移民！只是建造机器人基地，这个目标实现的可能还会更快！我认为马斯克完全可以不用考虑建造人类基地！完全可以搭建机器人基地，机器人比人类适应宇宙环境！所以建造月球基地基本上可以在2027年实现，然后3年内就可以基本实现火星基地建设，这个目标是在特斯拉机器人在2027年能够实现量产目标的前提。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/584677582881688","repostId":"2650902156","repostType":2,"repost":{"id":"2650902156","kind":"live","pubTimestamp":1783664772,"share":"https://www.laohunote.com/m/news/2650902156?lang=zh_CN&edition=full","pubTime":"2026-07-10 14:26","market":"us","language":"zh","title":"马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星","url":"https://stock-news.laohu8.com/highlight/detail?id=2650902156","media":"智通财经","summary":"【马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星】在一档最新节目中，马斯克表示，他希望在未来十年内将数万人送往月球基地，今年年底目标将第一批物资送往月球和火星，以开始建立殖民地。马斯克预计，未","content":"<html><body><div>\n<div>\n<b>【马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星】</b>在一档最新节目中，马斯克表示，他希望在未来十年内将数万人送往月球基地，今年年底目标将第一批物资送往月球和火星，以开始建立殖民地。马斯克预计，未来两到三年，SpaceX将先送宇航员上月球，然后以此为基础迅速扩张，在未来五年内将人类送到月球和火星，并在十年内在月球表面建立永久性城市。这座月球城市预计功能完备、能实现自给自足，人们既可以永久定居，也可以度假。不过，他也强调，送人上火星的难度要高得多，因为旅途耗时更漫长，不过SpaceX计划五年内实现送人登上火星，并有望在未来10到12年内将数千人送往那里。此外，他还对扩展太空数据中心一事作出更明确的承诺，称SpaceX将于明年发射首批人工智能卫星，随后在未来两年内进行大规模部署。 </div>\n</div></body></html>","source":"live_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 14:26 北京时间 <a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星】在一档最新节目中，马斯克表示，他希望在未来十年内将数万人送往月球基地，今年年底目标将第一批物资送往月球和火星，以开始建立殖民地。马斯克预计，未来两到三年，SpaceX将先送宇航员上月球，然后以此为基础迅速扩张，在未来五年内将人类送到月球和火星，并在十年内在月球表面建立永久性城市。这座月球城市预计功能完备、能实现自给自足，人们既可以永久定居，...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0082616367.USD":"摩根大通美国科技A（dist）","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","BK4099":"汽车制造商","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4555":"新能源车","SMOG":"VanEck Low Carbon Energy ETF","TSLO":"2倍上限加速TSLA ETF-Leverage Shares","LU0823411888.USD":"法巴消费创新基金 Cap","BK4592":"伊斯兰概念","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","FDRV":"Fidelity Electric Vehicles and Future Transportation ETF","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","BK4550":"红杉资本持仓","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","BK4551":"寇图资本持仓","BK4598":"佩洛西持仓","LU2063271972.USD":"富兰克林创新领域基金","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","07366":"南方两倍做空特斯拉","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU2290526834.HKD":"BGF NEXT GENERATION TECHNOLOGY \"A2\" (HKDHDG) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","TESL":"Simplify Volt TSLA Revolution ETF","TSDD":"2倍做空TSLA ETF-GraniteShares","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","TSYY":"收益增强TSLA ETF-GraniteShares","TEST":"YieldMax TSLA Performance & Distribution Target 25 ETF","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","LU0056508442.USD":"贝莱德世界科技基金A2","LU0823414478.USD":"法巴经典能源转换基金","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2403377893.USD":"ALLIANZ SELECT INCOME AND GROWTH \"AM\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","09766":"南方两倍做多特斯拉-U","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","BK4604":"机器人概念","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","TSLG":"2倍做多TSLA ETF-Leverage Shares","LU2360107168.USD":"BGF NEXT GENERATION TECHNOLOGY \"A4\" (USD) INC","BK4527":"明星科技股","TSL":"1.25倍做多TSLA ETF-GraniteShares","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","TSII":"REX TSLA Growth & Income ETF","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","07766":"南方两倍做多特斯拉","TSLI":"2倍做多TSLA ETF-ProShares","LU2420271590.USD":"ALLIANZ SELECT INCOME AND GROWTH \"AT\" (USD) ACC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","CRSH":"做空TSLA 期权收益策略ETF-YieldMax","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","TSLL":"2倍做多TSLA ETF-Direxion","LIT":"Global X Lithium & Battery Tech ETF","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","TSLP":"TSLA收益溢价策略ETF-Kurv","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4612":"AI芯片","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","TSLQ":"2倍做空TSLA ETF-Tradr","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"AG\" (USD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","TSLS":"1倍做空TSLA ETF-Direxion","TSLA":"特斯拉","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","TSLR":"2倍做多TSLA ETF-GraniteShares","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","BK4574":"无人驾驶","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","TSLT":"2倍做多TSLA ETF-T-Rex","LU1861558580.USD":"日兴方舟颠覆性创新基金B","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","HK0000914686.HKD":"GFI Global Select Equity Fund Class A (HKD)","TSLW":"TSLA周配息ETF-Roundhill","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","09366":"南方两倍做空特斯拉-U","BK4581":"高盛持仓","BK4543":"AI","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","TSLY":"TSLA期权收益策略ETF-YieldMax","HK0000914660.USD":"GFI Global Select Equity Fund Class A (USD)","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","TSLZ":"2倍做空TSLA ETF-T-Rex","BK4511":"特斯拉概念","TLA":"GraniteShares Autocallable TSLA ETF","BK4534":"瑞士信贷持仓","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK4588":"碎股","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1861215975.USD":"贝莱德新一代科技基金 A2","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","BK4516":"特朗普概念","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","BK4548":"巴美列捷福持仓","BK4585":"ETF&股票定投概念","WANT":"Direxion Daily Consumer Discretionary Bull 3x Shares","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","IDRV":"iShares Self-Driving EV and Tech ETF"},"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2650902156","content_text":"【马斯克绘太空蓝图：十年内建成月球城市 五年内载人登火星】在一档最新节目中，马斯克表示，他希望在未来十年内将数万人送往月球基地，今年年底目标将第一批物资送往月球和火星，以开始建立殖民地。马斯克预计，未来两到三年，SpaceX将先送宇航员上月球，然后以此为基础迅速扩张，在未来五年内将人类送到月球和火星，并在十年内在月球表面建立永久性城市。这座月球城市预计功能完备、能实现自给自足，人们既可以永久定居，也可以度假。不过，他也强调，送人上火星的难度要高得多，因为旅途耗时更漫长，不过SpaceX计划五年内实现送人登上火星，并有望在未来10到12年内将数千人送往那里。此外，他还对扩展太空数据中心一事作出更明确的承诺，称SpaceX将于明年发射首批人工智能卫星，随后在未来两年内进行大规模部署。","news_type":1,"symbols_score_info":{"TSDD":0.6,"TSLG":0.6,"TSLI":0.6,"LIT":0.6,"TSLO":0.6,"TSLZ":0.6,"TLA":0.6,"CRSH":0.6,"TEST":0.6,"TSLW":0.6,"SMOG":0.6,"TSLY":0.6,"TSYY":0.6,"09366":0.6,"TSLR":0.6,"07366":0.6,"TSLS":0.6,"IDRV":0.6,"07766":0.6,"TSLA":1.78,"WANT":0.6,"TSLQ":0.6,"TSII":0.6,"09766":0.6,"TSLP":0.6,"TESL":0.6,"TSLL":0.6,"TSLT":0.6,"TSL":0.6,"FDRV":0.6}},"isVote":1,"tweetType":1,"viewCount":312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":584675076048256,"gmtCreate":1783774445521,"gmtModify":1783774447798,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] ","listText":"机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭] ","text":"机器人本来就是为了星际资源才发展的！Ai和机器人未来的目标是星辰大海，你不会就以为为了给你做一些服务的吧？未来机器人将会从宇宙中带回来无尽的资源和能量！那才是星辰大海！蓝星这点资源和有些人的短视根本不值一提，还有人怕什么机器人灭绝人类，这想法才真可笑，人家机器人的核心资源在星辰大海里！蓝星这点东西也就那些短视的人才当个宝贝一样捧着了[笑哭] [笑哭] [笑哭]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/584675076048256","repostId":"2650009089","repostType":2,"repost":{"id":"2650009089","kind":"news","pubTimestamp":1783668300,"share":"https://www.laohunote.com/m/news/2650009089?lang=zh_CN&edition=full","pubTime":"2026-07-10 15:25","market":"us","language":"zh","title":"SpaceX公布太空移民新规划：拟于2026年底前启动发射，特斯拉机器人将成首批“居民”","url":"https://stock-news.laohu8.com/highlight/detail?id=2650009089","media":"环球市场播报","summary":"SpaceX创始人埃隆·马斯克近日公布了其太空移民计划的最新时间表。该计划拟于2026年底前启动火箭发射，将首批建设物资运往月球和火星。据悉，特斯拉研发的“擎天柱”人形机器人将作为首批“居民”先行进驻，负责太空基础设施的早期搭建工作。 根据最新规划，SpaceX已调整战略重心。 作为该计划的阶段性进展，SpaceX于当地时间周四利用“猎鹰9号”可重复使用火箭，成功将29颗“星链”卫星送入低地球轨道。","content":"<html><body><div>\n<p> SpaceX创始人埃隆·马斯克近日公布了其太空移民计划的最新时间表。该计划拟于2026年底前启动火箭发射，将首批建设物资运往月球和火星。据悉，<span><a href=\"https://laohu8.com/S/TSLA\">特斯拉</a></span><span></span>研发的“擎天柱”（Optimus）人形机器人将作为首批“居民”先行进驻，负责太空基础设施的早期搭建工作。</p>\n<p> 根据最新规划，SpaceX已调整战略重心。马斯克此前表示，鉴于在月球建立基地的速度相对更快，公司目前正集中力量推进“月球城”建设，并计划在未来10年内正式<a href=\"https://laohu8.com/S/01630\">建成</a>。与此同时，他预计将在7年内向火星运送首批物资，并力争在2045年至2055年间，在火星上建成首个可自给自足的城市。</p>\n<p> 为支撑庞大的太空常态化运输与通信需求，SpaceX本周已向美国联邦通信委员会（FCC）递交申请，计划发射由10万颗卫星组成的全新卫星<a href=\"https://laohu8.com/S/STZ\">星座</a>。SpaceX创始团队成员吉姆·坎特雷尔（Jim Cantrell）对此表示，该卫星网络旨在全面提升地球与太空之间的通信效率，并为数以亿计的集中式人工智能（AI）设备提供核心算力。坎特雷尔强调，在人类正式抵达前，将由具备高效AI系统的机器人先行完成基地的建设与整备。</p>\n<p> 作为该计划的阶段性进展，SpaceX于当地时间周四利用“猎鹰9号”可重复使用火箭，成功将29颗“星链”卫星送入低地球轨道。马斯克在社交平台表示，为了运载建设太空定居点所需的重型机械，公司未来计划研发一款体量超越现役“星舰”（Starship）的超大型运输火箭。</p>\n<p> 然而，多位<a href=\"https://laohu8.com/S/000901\">航天</a>领域专家指出，该宏大计划在技术层面仍面临诸多严峻挑战。美国国家航空<a href=\"https://laohu8.com/S/00031\">航天</a>局（NASA）马歇尔航天飞行中心前首席技术官莱斯·约翰逊（Les Johnson）分析认为，实现廉价且可往返的航天运输是当前的首要瓶颈。尽管“星舰”此前已完成发射、回收及阶段性分离测试，但关键的“轨道空间燃料加注”技术尚未得到成功验证。</p>\n<p> 行业专家普遍认为，由于月球距离地球较近，往返仅需约3天，因此将作为火星移民计划的关键试验场。在月球基地建设中积累的物资卸载、太阳能发电、水氧循环以及栖息地建造等经验，后续将直接应用到长达6个月航程的火星探测任务中。</p>\n<p> 针对为何选择机器人作为先遣队，坎特雷尔指出，相较于生命保障系统极其复杂的生命体，人形机器人仅需太阳能电力和定期维护，在恶劣的太空生存环境中具有显著的保障优势。这一战略将集中整合马斯克旗下xAI公司的人工智能技术与特斯拉的硬件制造能力。关于物资保障及基地选址等核心生存要素，目前相关科研团队仍在进行可行性论证。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：龙运翔 </p>\n</div></body></html>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SpaceX公布太空移民新规划：拟于2026年底前启动发射，特斯拉机器人将成首批“居民”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpaceX公布太空移民新规划：拟于2026年底前启动发射，特斯拉机器人将成首批“居民”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 15:25 北京时间 <a href=https://finance.sina.com.cn/stock/usstock/c/2026-07-10/doc-inihhzry7166085.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SpaceX创始人埃隆·马斯克近日公布了其太空移民计划的最新时间表。该计划拟于2026年底前启动火箭发射，将首批建设物资运往月球和火星。据悉，特斯拉研发的“擎天柱”（Optimus）人形机器人将作为首批“居民”先行进驻，负责太空基础设施的早期搭建工作。\n 根据最新规划，SpaceX已调整战略重心。马斯克此前表示，鉴于在月球建立基地的速度相对更快，公司目前正集中力量推进“月球城”建设，并计划在未来...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-10/doc-inihhzry7166085.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLW":"TSLA周配息ETF-Roundhill","IDRV":"iShares Self-Driving EV and Tech ETF","TSII":"REX TSLA Growth & Income ETF","TSLA":"特斯拉","UFO":"Procure Space ETF","TSLY":"TSLA期权收益策略ETF-YieldMax","TSDD":"2倍做空TSLA ETF-GraniteShares","SPCX":"SPAC and New Issue ETF","META":"Meta Platforms, Inc.","TSL":"1.25倍做多TSLA ETF-GraniteShares","AAPL":"苹果","TSLZ":"2倍做空TSLA ETF-T-Rex","YMAG":"YieldMax Magnificent 7 Fund of Option Income ETF","TESL":"Simplify Volt TSLA Revolution ETF","TLA":"GraniteShares Autocallable TSLA ETF","TSLG":"2倍做多TSLA ETF-Leverage Shares","ROBO":"全球机器人自动化ETF-ROBO","TSYY":"收益增强TSLA ETF-GraniteShares","TEST":"YieldMax TSLA Performance & Distribution Target 25 ETF","TSLI":"2倍做多TSLA ETF-ProShares","SMOG":"VanEck Low Carbon Energy ETF","BULZ":"MicroSectors FANG & Innovation 3X Leveraged ETN","TSLL":"2倍做多TSLA ETF-Direxion","CRSH":"做空TSLA 期权收益策略ETF-YieldMax","07766":"南方两倍做多特斯拉","DXYZ":"Destiny Tech100 Inc","LIT":"Global X Lithium & Battery Tech ETF","TSLP":"TSLA收益溢价策略ETF-Kurv","TSLO":"2倍上限加速TSLA ETF-Leverage Shares","MAGY":"Roundhill Magnificent Seven Covered Call ETF","TSLQ":"2倍做空TSLA ETF-Tradr","XOVR":"ERShares Private-Public Crossover ETF","SNK":"2倍做空SpaceX ETF-GraniteShares","GOOG":"谷歌","MSFT":"微软","SPCU":"2倍做多SpaceX ETF-Defiance","FDRV":"Fidelity Electric Vehicles and Future Transportation ETF","NVDA":"英伟达","TSLR":"2倍做多TSLA ETF-GraniteShares","SPAL":"2倍做多Space X ETF-GraniteShares","SPCF":"2倍做多SpaceX ETF-ProShares","WANT":"Direxion Daily Consumer Discretionary Bull 3x Shares","TSLS":"1倍做空TSLA ETF-Direxion","AMZN":"亚马逊","LOFF":"2倍做多SpaceX ETF-Direxion","SPCG":"2倍做空SpaceX ETF-Tradr","KOMP":"SPDR S&P Kensho New Economies Composite ETF","TSLT":"2倍做多TSLA ETF-T-Rex","SPCH":"2倍做多SpaceX ETF-Leverage Shares"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-10/doc-inihhzry7166085.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2650009089","content_text":"SpaceX创始人埃隆·马斯克近日公布了其太空移民计划的最新时间表。该计划拟于2026年底前启动火箭发射，将首批建设物资运往月球和火星。据悉，特斯拉研发的“擎天柱”（Optimus）人形机器人将作为首批“居民”先行进驻，负责太空基础设施的早期搭建工作。\n 根据最新规划，SpaceX已调整战略重心。马斯克此前表示，鉴于在月球建立基地的速度相对更快，公司目前正集中力量推进“月球城”建设，并计划在未来10年内正式建成。与此同时，他预计将在7年内向火星运送首批物资，并力争在2045年至2055年间，在火星上建成首个可自给自足的城市。\n 为支撑庞大的太空常态化运输与通信需求，SpaceX本周已向美国联邦通信委员会（FCC）递交申请，计划发射由10万颗卫星组成的全新卫星星座。SpaceX创始团队成员吉姆·坎特雷尔（Jim Cantrell）对此表示，该卫星网络旨在全面提升地球与太空之间的通信效率，并为数以亿计的集中式人工智能（AI）设备提供核心算力。坎特雷尔强调，在人类正式抵达前，将由具备高效AI系统的机器人先行完成基地的建设与整备。\n 作为该计划的阶段性进展，SpaceX于当地时间周四利用“猎鹰9号”可重复使用火箭，成功将29颗“星链”卫星送入低地球轨道。马斯克在社交平台表示，为了运载建设太空定居点所需的重型机械，公司未来计划研发一款体量超越现役“星舰”（Starship）的超大型运输火箭。\n 然而，多位航天领域专家指出，该宏大计划在技术层面仍面临诸多严峻挑战。美国国家航空航天局（NASA）马歇尔航天飞行中心前首席技术官莱斯·约翰逊（Les Johnson）分析认为，实现廉价且可往返的航天运输是当前的首要瓶颈。尽管“星舰”此前已完成发射、回收及阶段性分离测试，但关键的“轨道空间燃料加注”技术尚未得到成功验证。\n 行业专家普遍认为，由于月球距离地球较近，往返仅需约3天，因此将作为火星移民计划的关键试验场。在月球基地建设中积累的物资卸载、太阳能发电、水氧循环以及栖息地建造等经验，后续将直接应用到长达6个月航程的火星探测任务中。\n 针对为何选择机器人作为先遣队，坎特雷尔指出，相较于生命保障系统极其复杂的生命体，人形机器人仅需太阳能电力和定期维护，在恶劣的太空生存环境中具有显著的保障优势。这一战略将集中整合马斯克旗下xAI公司的人工智能技术与特斯拉的硬件制造能力。关于物资保障及基地选址等核心生存要素，目前相关科研团队仍在进行可行性论证。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：龙运翔","news_type":1,"symbols_score_info":{"TEST":0.6,"TLA":0.6,"TSLQ":0.6,"IDRV":0.6,"MAGY":1.5,"XOVR":1.5,"SPAL":1.5,"TSLP":0.6,"UFO":0.6,"LIT":0.6,"TSLL":1.5,"YMAG":1.5,"NVDA":0.6,"SNK":1.5,"TSII":0.6,"TSDD":0.6,"TSLG":0.6,"TSLO":0.6,"SPCG":0.6,"TSLY":0.6,"DXYZ":1.5,"WANT":0.6,"SPCF":0.6,"FDRV":0.6,"CRSH":0.6,"KOMP":1.5,"SMOG":0.6,"ROBO":1.5,"TSLT":0.6,"SPCX":1.5,"TSYY":0.6,"AMZN":0.6,"TESL":0.6,"SPCH":0.6,"07766":0.6,"GOOG":0.6,"TSLR":0.6,"AAPL":0.6,"TSL":0.6,"TSLI":0.6,"MSFT":0.6,"LOFF":0.6,"BULZ":1.5,"META":0.6,"TSLS":0.6,"TSLW":0.6,"TSLZ":0.6,"TSLA":1.5,"SPCU":1.5}},"isVote":1,"tweetType":1,"viewCount":434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":377657355678040,"gmtCreate":1733238081989,"gmtModify":1733238083159,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> 持续关注","listText":"<a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$ </a> 持续关注","text":"$英特尔(INTC)$ 持续关注","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377657355678040","isVote":1,"tweetType":1,"viewCount":3078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":373504175784344,"gmtCreate":1732227332476,"gmtModify":1732227334575,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"[强][强][强]","listText":"[强][强][强]","text":"[强][强][强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373504175784344","isVote":1,"tweetType":1,"viewCount":3519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":212189702062136,"gmtCreate":1692822805880,"gmtModify":1692822806924,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a>重要提示！英伟达现在可以卖房买了！ <a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a><a href=\"https://laohu8.com/S/MSFT\">$微软(MSFT)$ </a>","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a>重要提示！英伟达现在可以卖房买了！ <a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a><a href=\"https://laohu8.com/S/MSFT\">$微软(MSFT)$ </a>","text":"$英伟达(NVDA)$ 重要提示！英伟达现在可以卖房买了！ $特斯拉(TSLA)$ $微软(MSFT)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/212189702062136","isVote":1,"tweetType":1,"viewCount":7954,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3554542575382015","authorId":"3554542575382015","name":"湖心渺渺长空低","avatar":"https://static.tigerbbs.com/6c97b068b07799b8b81c0196ec43dc59","crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3554542575382015","idStr":"3554542575382015"},"content":"是买英伟达还是特斯拉","text":"是买英伟达还是特斯拉","html":"是买英伟达还是特斯拉"},{"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"content":"继特斯拉之后的第二个造富潮来袭，把握好这波到2026年财富自由！","text":"继特斯拉之后的第二个造富潮来袭，把握好这波到2026年财富自由！","html":"继特斯拉之后的第二个造富潮来袭，把握好这波到2026年财富自由！"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":212137801765080,"gmtCreate":1692822299892,"gmtModify":1692822301016,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> 英伟达INVDA.0/2024财年第二季度营收135.1亿美元，上年同期67亿美元，，市场预期112.24亿美元。","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> 英伟达INVDA.0/2024财年第二季度营收135.1亿美元，上年同期67亿美元，，市场预期112.24亿美元。","text":"$英伟达(NVDA)$ 英伟达INVDA.0/2024财年第二季度营收135.1亿美元，上年同期67亿美元，，市场预期112.24亿美元。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/212137801765080","isVote":1,"tweetType":1,"viewCount":3197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":651692545,"gmtCreate":1681805350788,"gmtModify":1681805588082,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/FUT/BTCmain\">$CME比特币主连 2304(BTCmain)$ </a><a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$ </a><a href=\"https://laohu8.com/S/COIN\">$Coinbase Global, Inc.(COIN)$ </a> 大饼近期趋势震荡下行，以下市场消息均不利于加密货币近期走势。 1.国际清算银行行长，利率可能需要保持在更高水平，而且持续的时间可能比此前预期的要长。 2.【苹果与高盛合作的Apple Card高收益储蓄账户今日上线】金十数据4月17日讯，苹果公司官网4月17日宣布，与高盛合作的Apple Card高收益储蓄账户于今日上线，目前提供4.15%的年利率。一旦用户通过Apple Card设置了储蓄账户，来自Apple Card的每日奖励金会自动存入该账户。用户还可以通过一个关联的银行账户将资金存入储蓄账户，并且可以随时将资金转出到关联的银行账户，过程不收取任何费用。","listText":"<a href=\"https://laohu8.com/FUT/BTCmain\">$CME比特币主连 2304(BTCmain)$ </a><a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$ </a><a href=\"https://laohu8.com/S/COIN\">$Coinbase Global, Inc.(COIN)$ </a> 大饼近期趋势震荡下行，以下市场消息均不利于加密货币近期走势。 1.国际清算银行行长，利率可能需要保持在更高水平，而且持续的时间可能比此前预期的要长。 2.【苹果与高盛合作的Apple Card高收益储蓄账户今日上线】金十数据4月17日讯，苹果公司官网4月17日宣布，与高盛合作的Apple Card高收益储蓄账户于今日上线，目前提供4.15%的年利率。一旦用户通过Apple Card设置了储蓄账户，来自Apple Card的每日奖励金会自动存入该账户。用户还可以通过一个关联的银行账户将资金存入储蓄账户，并且可以随时将资金转出到关联的银行账户，过程不收取任何费用。","text":"$CME比特币主连 2304(BTCmain)$ $Riot Blockchain, Inc.(RIOT)$ $Coinbase Global, Inc.(COIN)$ 大饼近期趋势震荡下行，以下市场消息均不利于加密货币近期走势。 1.国际清算银行行长，利率可能需要保持在更高水平，而且持续的时间可能比此前预期的要长。 2.【苹果与高盛合作的Apple Card高收益储蓄账户今日上线】金十数据4月17日讯，苹果公司官网4月17日宣布，与高盛合作的Apple Card高收益储蓄账户于今日上线，目前提供4.15%的年利率。一旦用户通过Apple Card设置了储蓄账户，来自Apple Card的每日奖励金会自动存入该账户。用户还可以通过一个关联的银行账户将资金存入储蓄账户，并且可以随时将资金转出到关联的银行账户，过程不收取任何费用。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/651692545","isVote":1,"tweetType":1,"viewCount":5330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":807466328,"gmtCreate":1628051040664,"gmtModify":1628051040664,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"扎克排名很重要，希望多发一些","listText":"扎克排名很重要，希望多发一些","text":"扎克排名很重要，希望多发一些","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807466328","repostId":"2155841281","repostType":2,"isVote":1,"tweetType":1,"viewCount":3085,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":807469846,"gmtCreate":1628050746185,"gmtModify":1628050746185,"author":{"id":"3479576576056160","authorId":"3479576576056160","name":"东东南亚","avatar":"https://static.tigerbbs.com/d8c94e66f07db4943f9b584d30f6937f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3479576576056160","idStr":"3479576576056160"},"themes":[],"title":"","htmlText":"一切看成果，没有成果的事情都是耍流氓。","listText":"一切看成果，没有成果的事情都是耍流氓。","text":"一切看成果，没有成果的事情都是耍流氓。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/807469846","repostId":"1124757232","repostType":2,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohunote.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NARI":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":4451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}